ArticleFrontiers in pharmacology2025
Association of dexmedetomidine with short-term outcome in patients with cardiogenic shock: a retrospective propensity score-matched cohort study from MIMIC-IV.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexmedetomidine has been demonstrated to have cardioprotective effects in previous studies, prompting our investigation into its potential to improve survival outcomes in patients with cardiogenic shock (CS). Methods: This retrospective cohort study analyzed data from the Medical Information Mart for Intensive Care (MIMIC) IV database, focusing on patients with CS. Exposure was defined as intravenous dexmedetomidine administration during intensive care unit (ICU) stay. The primary endpoints included 7-day and 30-day all-cause mortality. External validation was conducted using the eICU 2.0 database. Results: The pre-matched and propensity score matched cohorts comprised 2,341 and 1,038 patients, respectively. Multivariable Cox regression analysis of the overall cohort revealed that dexmedetomidine administration was significantly associated with reduced risk of both 7-day (hazard ratio (HR) = 0.473, 95% confidence interval (CI): 0.359-0.624, p < 0.001) and 30-day all-cause mortality (HR = 0.606, 95% CI: 0.500-0.735, p < 0.001). This protective association persisted after propensity score matching (PSM) for 7-day (HR = 0.418, 95% CI: 0.317-0.552, p < 0.001) and 30-day mortality (HR = 0.579, 95% CI: 0.475-0.705, p < 0.001). Subgroup analyses demonstrated that patients older than 75 years, those with chronic pulmonary disease, or those with lower systolic blood pressure may not benefit from dexmedetomidine. External validation using 1411 CS patients from the eICU 2.0 database confirmed these findings, with PSM-adjusted analyses showing reduced in-hospital (HR = 0.597; 95% CI: 0.395-0.901; p = 0.014) and in-ICU mortality (HR = 0.425; 95% CI: 0.262-0.689; p < 0.001) among dexmedetomidine treated patients. Conclusion: Dexmedetomidine administration was associated with reduced risk of 7-day and 30-day all-cause mortality in CS patients, though this protective effect may not be significant in patients over 75 years, those with chronic pulmonary disease, or those with lower systolic blood pressure. Prospective studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.